日本宫颈癌疫苗新增两项严重副作用

2013-06-03 佚名 39健康网

  5月28日,日本厚生劳动省针对子宫颈癌疫苗Cervarix可引发的严重副作用发布最新说明。该说明新增“急性播散性脑脊髓炎(ADEM)”和“格林巴利综合征(Guillain-Barresyndrome,GBS)”两项严重副作用,并已引起日本各医疗机关的注意。   据称,该疫苗在日本已上市3年,累积约273万人注射疫苗。在此其间,接到运动障碍、痉挛症状的急性播散性脑脊髓炎报告共3例,手脚肌肉麻痹

  5月28日,日本厚生劳动省针对子宫颈癌疫苗Cervarix可引发的严重副作用发布最新说明。该说明新增“急性播散性脑脊髓炎(ADEM)”和“格林巴利综合征(Guillain-Barresyndrome,GBS)”两项严重副作用,并已引起日本各医疗机关的注意。

  据称,该疫苗在日本已上市3年,累积约273万人注射疫苗。在此其间,接到运动障碍、痉挛症状的急性播散性脑脊髓炎报告共3例,手脚肌肉麻痹症状的格林巴利综合征报告共5例,无死亡报告。日本厚生劳动省于今年3月末修改了针对该子宫颈癌疫苗的相关说明。

  日本于4月开始开展该子宫颈癌疫苗的定期预防接种,接种对象为小学六年级到高中一年级的女性。除Cervarix子宫颈癌疫苗外,其他厂家生产的子宫颈癌疫苗也将陆续将说明书更新为最新说明书。



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1824176, encodeId=aeb418241e623, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Sep 22 06:41:00 CST 2013, time=2013-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663715, encodeId=5ac41663e159c, content=<a href='/topic/show?id=6a124631390' target=_blank style='color:#2F92EE;'>#宫颈癌疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46313, encryptionId=6a124631390, topicName=宫颈癌疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=077725685033, createdName=12498adam48暂无昵称, createdTime=Fri Mar 28 16:41:00 CST 2014, time=2014-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294129, encodeId=cd5e1294129b1, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jun 05 02:41:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407901, encodeId=260f140e90100, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Wed Jun 05 02:41:00 CST 2013, time=2013-06-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1824176, encodeId=aeb418241e623, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Sep 22 06:41:00 CST 2013, time=2013-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663715, encodeId=5ac41663e159c, content=<a href='/topic/show?id=6a124631390' target=_blank style='color:#2F92EE;'>#宫颈癌疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46313, encryptionId=6a124631390, topicName=宫颈癌疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=077725685033, createdName=12498adam48暂无昵称, createdTime=Fri Mar 28 16:41:00 CST 2014, time=2014-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294129, encodeId=cd5e1294129b1, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jun 05 02:41:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407901, encodeId=260f140e90100, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Wed Jun 05 02:41:00 CST 2013, time=2013-06-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1824176, encodeId=aeb418241e623, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Sep 22 06:41:00 CST 2013, time=2013-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663715, encodeId=5ac41663e159c, content=<a href='/topic/show?id=6a124631390' target=_blank style='color:#2F92EE;'>#宫颈癌疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46313, encryptionId=6a124631390, topicName=宫颈癌疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=077725685033, createdName=12498adam48暂无昵称, createdTime=Fri Mar 28 16:41:00 CST 2014, time=2014-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294129, encodeId=cd5e1294129b1, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jun 05 02:41:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407901, encodeId=260f140e90100, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Wed Jun 05 02:41:00 CST 2013, time=2013-06-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1824176, encodeId=aeb418241e623, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Sep 22 06:41:00 CST 2013, time=2013-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663715, encodeId=5ac41663e159c, content=<a href='/topic/show?id=6a124631390' target=_blank style='color:#2F92EE;'>#宫颈癌疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46313, encryptionId=6a124631390, topicName=宫颈癌疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=077725685033, createdName=12498adam48暂无昵称, createdTime=Fri Mar 28 16:41:00 CST 2014, time=2014-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294129, encodeId=cd5e1294129b1, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed Jun 05 02:41:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407901, encodeId=260f140e90100, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Wed Jun 05 02:41:00 CST 2013, time=2013-06-05, status=1, ipAttribution=)]
    2013-06-05 一闲

相关资讯

美国阴道镜检查和宫颈病理学会公布2013版宫颈癌筛查和癌前病变管理指南

美国阴道镜检查和宫颈病理学会(ASCCP)近日公布宫颈癌筛查和癌前病变管理共识指南。指南的制定和完善得益于医生和其他同仁为改善临床技能和患者预后而做出的孜孜不倦的努力,得益于为降低生殖道功能紊乱等疾病而做出的持之以恒的研究、预防、诊断、和管理等各方面的进步。针对以下常见问题,ASCCP给出了回答,告诉医生该指南将对目前的临床实践产生怎样的影响。指南全文见http://www.ASCCP.org/C

SGO:无铂化疗不能提高宫颈癌患者生存率

  3月10日,来自加利福尼亚大学欧文医学院的Krishnansu Tewari博士在2013年SGO妇科肿瘤年会上发表了最新一项研究成果:与标准化疗法相比,无铂化疗不能提高晚期宫颈癌患者的生存率,但其有作为替代疗法的潜力。   托泊替康-紫杉醇新二联化疗患者总生存数(OS)中位数为12.5个月,顺铂-紫杉醇二联化疗患者OS中位数为15个月,二者差异无统计学意义。卵巢癌患者行顺铂

托泊替康-紫杉醇化疗不优于顺铂-紫杉醇

       考虑到晚期或复发性宫颈癌患者可选择的化疗药有限,Tewari博士和他所在妇科肿瘤组其他研究者进行了一项随机比对临床试验,来评估无铂化疗对晚期、难治性或复发性宫颈癌患者疗效。   研究对象为452名IVB期复发性、难治性或转移的宫颈癌患者,75%(339名)患者既往采用以铂为基础的化疗。研究人员将患者随机分组,分别给予顺铂-紫杉醇、托泊替

科学家研发DNA产品识别高危宫颈癌

  据美国《星岛日报》报道,全美女性死亡人数最多的疾病是宫颈癌,人类乳突病毒(HPV)是致病主要元凶。但是,感染HPV病毒并不意味着未来必罹患癌症,全美75%的女性和五成男性在一生中会感染HPV,两位女性华裔生命科学家温可仪、郑淑玲共同创办的公司,以HPV DNA技术明确地界定病例是否为临时感染或致癌隐患,大大降低社会医疗成本。   温可仪表示,宫颈癌是全美女性最大的杀手,也是全球妇女

HPV亚型检测有助于宫颈癌筛查

 美国新版指南推荐“联合检测”,高危基因亚型提示疾病预期 宫颈癌是世界第三大女性恶性肿瘤,是中国女性第二大最常见的恶性肿瘤。据世界卫生组织估计,全世界每年有逾47万新发宫颈癌病例,中国每年新发宫颈癌病例数 约占世界总发病数的28%。据权威机构估计,若缺乏适当、有效的筛查方法及预防计划,至2025年,亚洲的宫颈癌发病率将上升40%。 近年来,宫颈癌病因人类乳头状瘤病毒(HPV)的发现

Obstetrics Gynecol:美国更新宫颈癌筛查指南

  近日,美国阴道和子宫颈癌协会发布宫颈癌筛查异常和癌前病变处理指南。总体来看,目前的宫颈癌筛查间隔较长,30~64 岁女性每5 年筛查一次,应接受细胞学和人乳头状瘤病毒(HPV)检测。新版指南强调两种方法联合应用,旨在限制随访检查次数。该指南建议,风险相似的人群应采取相似的筛查策略。   该指南强调了筛查策略的安全性。指南不推荐对21~24 岁、细胞学检查异常程度